From ArteraAI: Results identified 40% of BCR patients who benefited from therapy intensification vs. 60% of patients who did not The data revealed during the 2024 AUA Annual Meeting displays promise for a more personalized...

ArteraAI: The funding will support the international expansion and commercial growth of the company and its first-of-its-kind test SAN FRANCISCO--(BUSINESS WIRE)--ArteraAI, the developer of multimodal artificial intelligence (MMAI) based...

ArteraAI, CorePlus collaboration aims to further validate the ArteraAI Prostate Test in the Hispanic population SAN FRANCISCO--(BUSINESS WIRE)--ArteraAI, the developer of multimodal artificial intelligence (MMAI) based predictive and...